MorphoSys has regained rights to MOR202 from Celgene Read the full story

Epizyme has reacquired global rights to its EZH2 program, including EPZ-6438, from its partner Eisai Read the full story

Pfizer issued to Repligen a notice of termination for convenience under the License Agreement, dated December 28, 2012 Read the full story

Merck KGaA is conducting an ongoing assessment of its pipeline assets and has decided to return the rights of Sym004 to Symphogen for further development Read the full story

Astellas Pharma announced that its license agreement with Janssen Biotech, to develop and commercialize ASP015K, oral Janus Kinase (JAK) inhibitor, will end Read the full story

Dynavax Technologies has regained full rights to DV1179, an investigational bifunctional inhibitor of toll-like receptors (TLR) 7 and 9 Read the full story

Grunenthal announced the termination of the license agreement with Actavis for the development and commercialization of Cebranopadol Read the full story

Inovio Pharmaceuticals announced Roche have terminated their 2013 collaboration, option, and license agreement to co-develop INO-5150 Read the full story

Novartis had signed an MOU for acquisition of the stem cell treatment company, Gamida Cell, for up to $600 million. Read the full story

The board member's Adcock Ingram Holdings, in South Africa, have voted against CFR Pharmaceuticals acquisition proposal. Read the full story